Company news
Modalis Therapeutics Corporation news in 2022
Modalis Therapeutics Corporation's news releases, calls and decks from 2022, newest first.
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
July 5, 2022
Notice Regarding a Patent Allowance for ‘Method for treating muscular dystrophy by targeting utrophin gene’ in the USA
June 22, 2022
Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)
June 15, 2022
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting
April 20, 2022
Modalis Therapeutics: Business Plans and Matters Related to High Growth Potential
March 29, 2022
Announcement of Issuance of Stock Options (Share Acquisition Rights)
March 29, 2022
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
February 22, 2022
Modalis Therapeutics Announces Termination of Research Collaboration on MDL-204
January 7, 2022